Tandem Diabetes Care Inc.

5 days ago · zacks.com

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

12 days ago · gurufocus.com

On September 10, 2026, Tandem Diabetes Care Inc (TNDM) shares fell 4.2% to a current price of $18.31. The stock has experienced notable volatility, trading betw

13 days ago · zacks.com

TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.

1 month ago · benzinga.com

On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.

1 month ago · zacks.com

Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.

2 months ago · marketbeat.com

Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.

2 months ago · seekingalpha.com

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.48 per share a year ago.

2 months ago · zacks.com

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

2 months ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in t.